Characterization and high‐yield production of non‐N‐glycosylated recombinant human BCMA‐Fc in Pichia pastoris
Sign Up to like & getrecommendations! Published in 2017 at "Engineering in Life Sciences"
DOI: 10.1002/elsc.201600039
Abstract: B‐cell maturation antigen (BCMA) fused at the C‐terminus to the Fc portion of human IgG1 (BCMA‐Fc) blocks B‐cell activating factor (BAFF) and proliferation‐inducing ligand (APRIL)‐mediated B‐cell activation, leading to immune disorders. The fusion protein has… read more here.
Keywords: recombinant human; production; bcma; human bcma ... See more keywords
The Role of B-Cell Maturation Antigen in the Biology and Management of, and as a Potential Therapeutic Target in, Multiple Myeloma
Sign Up to like & getrecommendations! Published in 2017 at "Targeted Oncology"
DOI: 10.1007/s11523-017-0538-x
Abstract: B-cell maturation antigen (BCMA) was originally identified as a cell membrane receptor, expressed exclusively on late stage B-cells and plasma cells (PCs). Investigations of BCMA as a target for therapeutic intervention in multiple myeloma (MM)… read more here.
Keywords: bcma; target; biology; antigen ... See more keywords
Selective targeting of multiple myeloma by B cell maturation antigen (BCMA)-specific central memory CD8+ cytotoxic T lymphocytes: immunotherapeutic application in vaccination and adoptive immunotherapy
Sign Up to like & getrecommendations! Published in 2019 at "Leukemia"
DOI: 10.1038/s41375-019-0414-z
Abstract: To expand the breadth and extent of current multiple myeloma (MM)-specific immunotherapy, we have identified various antigens on CD138+ tumor cells from newly diagnosed MM patients (n = 616) and confirmed B-cell maturation antigen (BCMA) as a… read more here.
Keywords: bcma specific; myeloma; bcma; memory cd8 ... See more keywords
Single VHH-directed BCMA CAR-T cells cause remission of relapsed/refractory multiple myeloma
Sign Up to like & getrecommendations! Published in 2021 at "Leukemia"
DOI: 10.1038/s41375-021-01269-3
Abstract: Chimeric antigen receptor T (CAR-T) cells have shown remarkable effects in treating hematological malignancies [1, 2]. Typically, the antigen recognition domain of CAR-T cells is a single-chain variable fragment (scFv) linked to a costimulatory domain… read more here.
Keywords: chain; heavy chain; bcma; vhh ... See more keywords
CXCR4 and anti-BCMA CAR co-modified natural killer cells suppress multiple myeloma progression in a xenograft mouse model.
Sign Up to like & getrecommendations! Published in 2021 at "Cancer gene therapy"
DOI: 10.1038/s41417-021-00365-x
Abstract: The highly restricted expression of B-cell maturation antigen (BCMA) on plasma cells makes it an ideal target for chimeric antigen receptor (CAR) immune cell therapy against multiple myeloma (MM), a bone marrow cancer. To improve… read more here.
Keywords: bcma; natural killer; multiple myeloma; cxcr4 ... See more keywords
Soluble TACI and soluble BCMA as biomarkers in primary central nervous system lymphoma
Sign Up to like & getrecommendations! Published in 2017 at "Neuro-Oncology"
DOI: 10.1093/neuonc/nox097
Abstract: Background B-cell survival is regulated through interactions of B-cell-activating factor and a proliferation-inducing ligand with their receptors transmembrane activator and CAML interactor (TACI) and B-cell maturation antigen (BCMA). We evaluated the diagnostic potential of soluble… read more here.
Keywords: soluble bcma; soluble taci; bcma; sbcma ... See more keywords
Anti-BCMA CAR-T cells therapy for a patient with extremely high membrane BCMA expression: a case report
Sign Up to like & getrecommendations! Published in 2022 at "Journal for Immunotherapy of Cancer"
DOI: 10.1136/jitc-2022-005403
Abstract: B cell maturation antigen (BCMA)-directed CAR-T cell therapy is a disruptive approach for treating relapsed/refractory multiple myeloma (R/R MM); however, optimization is necessary to maximize patient benefit. We report the case of a 61-year-old woman… read more here.
Keywords: bcma; expression; case; membrane bcma ... See more keywords
Abstract LB-299: Cynomolgus monkey plasma cell gene signature to quantify the in vivo activity of a half-life extended anti-BCMA BiTE® for the treatment of multiple myeloma
Sign Up to like & getrecommendations! Published in 2018 at "Cancer Research"
DOI: 10.1158/1538-7445.am2018-lb-299
Abstract: Background: Multiple myeloma (MM) is a hematologic malignancy where abnormal plasma cells (PC) accumulate in the bone marrow (BM). Patients often develop relapsed/refractory disease leading to significant morbidity and mortality. Elimination of residual disease is… read more here.
Keywords: bcma hle; bcma; bite; hle bite ... See more keywords
Abstract 4556: Preclinical pharmacology and safety of RO7297089, a novel anti-BCMA/CD16a bispecific antibody for the treatment of multiple myeloma
Sign Up to like & getrecommendations! Published in 2020 at "Immunology"
DOI: 10.1158/1538-7445.am2020-4556
Abstract: RO7297089 is a bispecific antibody (IgG-scFv) targeting Bcell maturation antigen (BCMA) and CD16a (FcγRIIIA) that is being developed for the treatment of multiple myeloma (MM). BCMA is exclusively expressed on plasmablasts and differentiated plasma cells… read more here.
Keywords: ro7297089; treatment; bcma; cd16a ... See more keywords
Abstract 5630: Anti-BCMA bispecific tool therapy against Vk*MYC multiple myeloma is enhanced by IMiDs
Sign Up to like & getrecommendations! Published in 2020 at "Immunology"
DOI: 10.1158/1538-7445.am2020-5630
Abstract: BCMA is an ideal target antigen for myeloma immunotherapy as it is specifically expressed by plasma cells and T cell-engaging, BCMA-bispecific antibodies show potent tumor killing activity in human multiple myeloma (MM). However, a lack… read more here.
Keywords: bcma bispecific; myeloma; bcma; therapy ... See more keywords
Abstract 1883: A novel T cell engager targeting BCMA and GPRC5D showed promising preclinical activity with low toxic risk for multiple myeloma treatment
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-1883
Abstract: Background: Multiple myeloma (MM) has become the second most hematological malignance. The patients are rarely cured and experience the recurrence or resistance. There is still an urgent need to develop potential therapeutic agents with better… read more here.
Keywords: cell; gprc5d; bcma; scr 8572 ... See more keywords